The Saura‘s lab at the Universitat Autònoma de Barcelona investigates the cellular and molecular mechanisms involved in the pathogenesis of cognitive disorders, particularly in Alzheimer’s disease.

Our research efforts are currently focused on understanding how brain functions during memory processing and the cellular and molecular mechanisms involved in brain dysfunction, memory loss and neurodegeneration in age-related cognitive disorders. Our lab combines molecular approaches and cutting-edge genomic, transcriptomic and proteomic methodologies to better understand the molecular pathways causing neuronal dysfunction, memory loss and neurodegeneration in Alzheimer’s disease.

Dr. Carles Saura’s lab investigates the transcriptional pathways that regulate synaptic plasticity underlying cognition and memory, which allows a better understanding of the mechanisms mediating gene expression changes causing synaptic dysfunction and memory loss in cognitive disorders, especially in Alzheimer’s disease.

We use pioneering approaches to generate novel transgenic and knockout mouse models of neurodegeneration that are used for testing new therapeutic strategies (pharmacological, gene therapy, cognitive stimulation…) for future treatment of age-related dementia disorders. Our research projects provide knowledge of novel molecular targets and therapeutic strategies for early treatment of Alzheimer’s disease and related neurological disorders.

Our investigations focus in three main topics:

1. Cellular mechanisms in Alzheimer’s  disease.

2. Novel research tools and models of neurodegeneration.

3. Therapies for Alzheimer’s  disease and cognitive disorders.

Lab news…

Researchers at Saura's laboratory

Our new Review ¨Synapse-to-nucleus signaling in neurodegenerative and neuropsychiatric diseases¨ is published today in Biological Psychiatry, the official journal of Society of Biological Psychiatry. 15 July, 2019Read more

A new biomarker in blood in early Alzheimer’s disease. Our new discovery published in the journal Alzheimer’s Research and Therapy identifies a new molecular signature of miRNAs in blood at early Alzheimer’s disease stages. May 17, 2019. Read more

Funded LLAVOR project. The project ¨Evaluation of novel compounds to enhance neuronal activity in Alzheimer’s disease¨, 2018 Llavor 00053,  funded with FEDER funds by Agencia de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), Secretaria d’Universitat i Recerca del Departament d’Empresa i Coneixement de la Generalitat de Catalunya. The project aims to evaluate novel pharmacological compounds to treat Alzheimer’s disease.  May 1, 2019. Read more

The Saura lab is actively exploring and developing research on the following topics: